{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:06:49Z","timestamp":1791090409228,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.neuint.2013.01.021","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T19:52:37Z","timestamp":1359143557000},"page":"349-353","source":"Crossref","is-referenced-by-count":6,"title":["Motor behavior correlates with striatal [18F]-DOPA uptake in MPTP-lesioned primates"],"prefix":"10.1016","volume":"62","author":[{"given":"R.","family":"Kortekaas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Eshuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Andringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2013.01.021_b0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00008877-199903000-00006","article-title":"The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson\u2019s disease: effects of L-DOPA and the D1 agonist SKF 82958","volume":"10","author":"Andringa","year":"1999","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuint.2013.01.021_b0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0969-9961(03)00125-6","article-title":"TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates","volume":"14","author":"Andringa","year":"2003","journal-title":"Neurobiol. Dis."},{"issue":"Suppl.","key":"10.1016\/j.neuint.2013.01.021_b0005","first-page":"215","article-title":"The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson\u2019s disease, the bilaterally MPTP-treated rhesus monkey","author":"Andringa","year":"2000","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuint.2013.01.021_b0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.nbd.2010.03.006","article-title":"Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An [18F]-DOPA and [11C]-DTBZ PET study","volume":"38","author":"Blesa","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.neuint.2013.01.021_b0025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1212\/WNL.0b013e318248e520","article-title":"Role of DaTSCAN and clinical diagnosis in Parkinson disease","volume":"78","author":"de la Fuente-Fern\u00e1ndez","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2013.01.021_b0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1353-8020(98)00025-X","article-title":"Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys","volume":"4","author":"de Yebenes","year":"1998","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neuint.2013.01.021_b0035","first-page":"1324","article-title":"Comparative analysis of striatal FDOPA uptake in Parkinson\u2019s disease: ratio method versus graphical approach","volume":"43","author":"Dhawan","year":"2002","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuint.2013.01.021_b0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004647-199903000-00006","article-title":"Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine","volume":"19","author":"Doudet","year":"1999","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuint.2013.01.021_b0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0006-8993(98)00710-0","article-title":"A novel MPTP primate model of Parkinson\u2019s disease: neurochemical and clinical changes","volume":"805","author":"Eberling","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2013.01.021_b0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0006-8993(99)01491-2","article-title":"Dopamine transporter loss and clinical changes in MPTP-lesioned primates","volume":"832","author":"Eberling","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2013.01.021_b0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/exnr.2000.7470","article-title":"Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys","volume":"165","author":"Eberling","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuint.2013.01.021_b0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1017\/S0317167100046369","article-title":"Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography","volume":"11","author":"Garnett","year":"1984","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2013.01.021_b0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF03165037","article-title":"Positron emission tomography with 4-[18F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys","volume":"9","author":"Hayase","year":"1995","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.neuint.2013.01.021_b0070","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.6403987","article-title":"Monkey model of Parkinson\u2019s disease","volume":"220","author":"Kolata","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuint.2013.01.021_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neuint.2008.04.010","article-title":"Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors-the cases of ketamine and haloperidol","volume":"53","author":"Kortekaas","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2013.01.021_b0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mds.870060205","article-title":"Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism","volume":"6","author":"Kurlan","year":"1991","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2013.01.021_b0085","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuint.2013.01.021_b0090","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","article-title":"Phase II\/III randomized trial of TCH346 in patients with ALS","volume":"69","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2013.01.021_b0095","first-page":"530","article-title":"TCH-346 (Novartis)","volume":"3","author":"M\u00fcck-Seler","year":"2000","journal-title":"IDrugs"},{"key":"10.1016\/j.neuint.2013.01.021_b0100","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(06)70602-0","article-title":"TCH346 as a neuroprotective drug in Parkinson\u2019s disease: a double-blind, randomised, controlled trial","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuint.2013.01.021_b0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jneumeth.2010.05.009","article-title":"Objective and quantitative evaluation of motor function in a monkey model of Parkinson\u2019s disease","volume":"190","author":"Saiki","year":"2010","journal-title":"J. Neurosci. Meth."},{"key":"10.1016\/j.neuint.2013.01.021_b0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0306-4522(93)90176-G","article-title":"Developing a stable bilateral model of parkinsonism in rhesus monkeys","volume":"52","author":"Smith","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2013.01.021_b0115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ana.410340304","article-title":"Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels","volume":"34","author":"Snow","year":"1993","journal-title":"Ann. Neurol."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018613000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018613000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T02:28:53Z","timestamp":1539916133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018613000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0197018613000247"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2013.01.021","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}